Atezolizumab as 1L therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma mUC: IMvigor210 cohort 1

Atezolizumab as 1L therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma mUC: IMvigor210 cohort 1

VJOncology

4 years
447 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Press brief by Arjun Vasant Balar, MD of the NYU Langone Medical Center, New York, NY, at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO), held in Chicago, IL.
Up Next Autoplay